Literature DB >> 21199926

Antimicrobial susceptibility of Brucella melitensis isolates in Peru.

Ryan C Maves1, Rosa Castillo, Alfredo Guillen, Benjamin Espinosa, Rina Meza, Nereyda Espinoza, Gladys Núñez, Luis Sánchez, Jesús Chacaltana, David Cepeda, Sofía González, Eric R Hall.   

Abstract

Brucellosis is an important public health problem in Peru. We evaluated 48 human Brucella melitensis biotype 1 strains from Peru between 2000 and 2006. MICs of isolates to doxycycline, azithromycin, gentamicin, rifampin, ciprofloxacin, and trimethoprim-sulfamethoxazole were determined by the Etest method. All isolates were sensitive to tested drugs during the periods of testing. Relapses did not appear to be related to drug resistance.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21199926      PMCID： PMC3067062          DOI： 10.1128/AAC.00979-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Actual antibiotic resistance pattern of Brucella melitensis in central Anatolia. An update from an endemic region.

Authors:  Esra Tanyel; Ahmet Y Coban; Suda T Koruk; Husniye Simsek; Serkan Hepsert; Osman S Cirit; Necla Tulek
Journal:  Saudi Med J       Date:  2007-08       Impact factor: 1.484

Review 2.  Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies.

Authors:  Matthew E Falagas; Ioannis A Bliziotis
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 3.  Brucellosis.

Authors:  Georgios Pappas; Nikolaos Akritidis; Mile Bosilkovski; Epameinondas Tsianos
Journal:  N Engl J Med       Date:  2005-06-02       Impact factor: 91.245

4.  Comparison of culture techniques at different stages of brucellosis.

Authors:  Benjamin J Espinosa; Jesús Chacaltana; Maximilian Mulder; María Pía Franco; David L Blazes; Robert H Gilman; Henk L Smits; Eric R Hall
Journal:  Am J Trop Med Hyg       Date:  2009-04       Impact factor: 2.345

5.  A practical method for routine blood cultures in brucellosis.

Authors:  M R CASTANEDA
Journal:  Proc Soc Exp Biol Med       Date:  1947-01

6.  Isolation of Brucella spp. from clinical specimens.

Authors:  H Etemadi; A Raissadat; M J Pickett; Y Zafari; P Vahedifar
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

7.  Azithromycin and gentamicin therapy for the treatment of humans with brucellosis.

Authors:  J Solera; J L Beato; E Martínez-Alfaro; J C Segura; E de Tomas
Journal:  Clin Infect Dis       Date:  2001-01-24       Impact factor: 9.079

8.  Susceptibility of Mexican brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis.

Authors:  Ahidé López-Merino; Araceli Contreras-Rodríguez; Roberto Migranas-Ortiz; Rubén Orrantia-Gradín; Gerardo M Hernández-Oliva; Arturo Torres Y Gutiérrez-Rubio; Oscar Cardeñosa
Journal:  Scand J Infect Dis       Date:  2004

9.  [Short communication: Investigation of in vitro antibiotic susceptibility of Brucella melitensis].

Authors:  Hikmet Alişkan; Tuba Turunç; Yusuf Ziya Demiroğlu; Sule Colakoğlu; Hande Arslan
Journal:  Mikrobiyol Bul       Date:  2008-01       Impact factor: 0.622

10.  Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations.

Authors:  Javier Ariza; Mile Bosilkovski; Antonio Cascio; Juan D Colmenero; Michael J Corbel; Matthew E Falagas; Ziad A Memish; Mohammad Reza Hasanjani Roushan; Ethan Rubinstein; Nikolaos V Sipsas; Javier Solera; Edward J Young; Georgios Pappas
Journal:  PLoS Med       Date:  2007-12       Impact factor: 11.069
View more
  12 in total

1.  Acquired Brucella bacteraemia in a young infant.

Authors:  Ambar Bhatnagar; Daisy Khera; Kuldeep Singh; Anuradha Sharma
Journal:  BMJ Case Rep       Date:  2017-04-07

Review 2.  Brucellosis in low-income and middle-income countries.

Authors:  Matthew P Rubach; Jo E B Halliday; Sarah Cleaveland; John A Crump
Journal:  Curr Opin Infect Dis       Date:  2013-10       Impact factor: 4.915

3.  Brucellosis, Taiwan, 2011.

Authors:  Yu-Chung Chuang; Szu-Chi Chen; Jung-Jung Mu; Hsiu-Ying Lin; Chih-Hsin Chang; Wei-Shiung Yang; Po-Ren Hsueh
Journal:  Emerg Infect Dis       Date:  2011-12       Impact factor: 6.883

4.  Reduced Susceptibility to Rifampicin and Resistance to Multiple Antimicrobial Agents among Brucella abortus Isolates from Cattle in Brazil.

Authors:  Rebeca Barbosa Pauletti; Ana Paula Reinato Stynen; Juliana Pinto da Silva Mol; Elaine Maria Seles Dorneles; Telma Maria Alves; Monalisa de Sousa Moura Souto; Silvia Minharro; Marcos Bryan Heinemann; Andrey Pereira Lage
Journal:  PLoS One       Date:  2015-07-16       Impact factor: 3.240

Review 5.  Retrospective and prospective perspectives on zoonotic brucellosis.

Authors:  Edgardo Moreno
Journal:  Front Microbiol       Date:  2014-05-13       Impact factor: 5.640

6.  Identification and in vitro antimicrobial susceptibility of Brucella species isolated from human brucellosis.

Authors:  Rohaidah Hashim; Norazah Ahmad; Jama'ayah Mohamed Zahidi; B Y Tay; Azura Mohd Noor; Sakina Zainal; Hazwani Hamzah; S H Hamzah; T S Chow; P S Wong; K N Leong
Journal:  Int J Microbiol       Date:  2014-07-10

7.  Brucella melitensis prosthetic joint infection.

Authors:  Domenica Flury; Henrik Behrend; Parham Sendi; Matthias von Kietzell; Carol Strahm
Journal:  J Bone Jt Infect       Date:  2017-04-05

8.  In vitro antibiotic susceptibility testing of Brucella isolates from Egypt between 1999 and 2007 and evidence of probable rifampin resistance.

Authors:  Mohamed Abdel-Maksoud; Brent House; Momtaz Wasfy; Bassem Abdel-Rahman; Guillermo Pimentel; Gehan Roushdy; Erica Dueger
Journal:  Ann Clin Microbiol Antimicrob       Date:  2012-08-28       Impact factor: 3.944

9.  The Antibacterial Activity of Selected Labiatae (Lamiaceae) Essential Oils against Brucella melitensis.

Authors:  Ayman Al-Mariri; Mazen Safi
Journal:  Iran J Med Sci       Date:  2013-03

10.  Whole-genome sequencing and antimicrobial resistance in Brucella melitensis from a Norwegian perspective.

Authors:  Tone B Johansen; Lonneke Scheffer; Veronica K Jensen; Jon Bohlin; Siri L Feruglio
Journal:  Sci Rep       Date:  2018-06-04       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.